KASUMI6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
AML · Acute Myeloid Leukemia
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
- subtype
- —
- cancer_type
- AML
- ccle_sample_id
- KASUMI6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
- synthetic_from_ccle
- true
- display_name
- Kasumi-6
- ccle_lineage
- blood
- ccle_lineage_subtype
- AML
- ccle_lineage_sub_subtype
- M2
- oncotree_code
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.545
- INTERFERON_ALPHA_RESPONSE+0.447
- INTERFERON_GAMMA_RESPONSE+0.427
- IL6_JAK_STAT3_SIGNALING+0.273
- INFLAMMATORY_RESPONSE+0.244
- DNA_REPAIR+0.174
- MYC_TARGETS_V2+0.155
- IL2_STAT5_SIGNALING+0.112
- SPERMATOGENESIS+0.082
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.076
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.658
- ANGIOGENESIS-0.610
- NOTCH_SIGNALING-0.497
- TGF_BETA_SIGNALING-0.469
- PROTEIN_SECRETION-0.420
- UV_RESPONSE_DN-0.395
- HEDGEHOG_SIGNALING-0.369
- GLYCOLYSIS-0.354
- ESTROGEN_RESPONSE_EARLY-0.333
- MYOGENESIS-0.332
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | KO52_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.878 |
| 2 | OCIAML2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.862 |
| 3 | EOL1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.846 |
| 4 | SRR2016954 | — | — | 0.846 |
| 5 | MOLM6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.838 |
| 6 | OCIAML5_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.836 |
| 7 | SRR8518222 | — | D | 0.818 |
| 8 | SRR6013594 | — | cohortMD2 | 0.810 |
| 9 | TCGA-62-A472-01A-11R-A24H-07 | — | cohortA1 | 0.809 |
| 10 | SRR5088834 | — | — | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.545 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.447 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.427 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.273 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.244 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.174 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.155 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.112 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.082 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.076 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.058 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.045 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| COMPLEMENT | 0.012 | Inavolisib | — uncovered |